Literature DB >> 28376561

A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry.

Tomasz Sacha1, Joanna Góra-Tybor2, Monika Szarejko3, Grażyna Bober4, Olga Grzybowska-Izydorczyk5, Joanna Niesiobędzka-Krężel6, Marek Dudziński7, Ewa Wasilewska8, Krzysztof Myśliwiec9, Justyna Gil10, Michał Gniot11, Iwona Pietkun12, Ewa Mędraś13, Jadwiga Hołojda14, Joanna Wącław1, Krzysztof Giannopoulos15.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28376561     DOI： 10.1002/ajh.24748

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  7 in total

1.  Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.

Authors:  Adi J Klil-Drori; Hui Yin; Laurent Azoulay; Michaël Harnois; Michel-Olivier Gratton; Lambert Busque; Sarit E Assouline
Journal:  Haematologica       Date:  2019-01-10       Impact factor: 9.941

Review 2.  Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.

Authors:  James A Kennedy; Gabriela Hobbs
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

3.  Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study.

Authors:  Maria Gemelli; Elena Maria Elli; Chiara Elena; Alessandra Iurlo; Tamara Intermesoli; Margherita Maffioli; Ester Pungolino; Maria Cristina Carraro; Mariella D'Adda; Francesca Lunghi; Michela Anghileri; Nicola Polverelli; Marianna Rossi; Mattia Bacciocchi; Elisa Bono; Cristina Bucelli; Francesco Passamonti; Laura Antolini; Carlo Gambacorti-Passerini
Journal:  Blood Res       Date:  2020-09-30

4.  Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Kiran Naqvi; Elias Jabbour; Jeffrey Skinner; Musa Yilmaz; Alessandra Ferrajoli; Prithviraj Bose; Philip Thompson; Yesid Alvarado; Nitin Jain; Koichi Takahashi; Jan Burger; Zeev Estrov; Gautam Borthakur; Naveen Pemmaraju; Shilpa Paul; Jorge Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2018-05-03       Impact factor: 6.860

Review 5.  Current status and novel strategy of CML.

Authors:  Kiyomi Morita; Koji Sasaki
Journal:  Int J Hematol       Date:  2021-03-29       Impact factor: 2.490

6.  [Efficacy, safety and health-related life quality of chronic myeloid leukemia during the chronic period switching from branded Gleevec or Tasigna to generic imatinib].

Authors:  T Zhao; L Yu; Y Z Qin; X J Huang; Y Hou; Q Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-09-14

Review 7.  Philadelphia Chromosome-Positive Leukemia in the Lymphoid Lineage-Similarities and Differences with the Myeloid Lineage and Specific Vulnerabilities.

Authors:  Lukasz Komorowski; Klaudyna Fidyt; Elżbieta Patkowska; Malgorzata Firczuk
Journal:  Int J Mol Sci       Date:  2020-08-12       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.